• 1
    Lawrence R, Helmick C, Arnett F, et al. 1998. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 41: 778779.
  • 2
    Rossdale PD, Hopes R, Digby NJW, et al. 1985. Epidemiological study of wastage among racehorses 1982 and 1983. Vet Rec 116: 6669.
  • 3
    USDA. 2000. Lameness and laminitis in U.S. horses. Fort Collins, CO: USDA:APHIA:VS, CEAH, National Animal Health Monitoring System; 34 p.
  • 4
    McIlwraith CW, Frisbie DD, Kawcak CE, et al. 2009. Recommendation of criteria for the evaluation of macroscopic and histological changes occurring in equine osteoarthritis. Osteoarthritis Cartilage (in press).
  • 5
    Frisbie DD, Al-Sobayil F, Billinghurst RC, et al. 2008. Changes in synovial fluid and serum biomarkers with exercise and early osteoarthritis in horses. Osteoarthritis Cartilage 16: 11961204.
  • 6
    Frisbie DD. 2005. Future directions in treatment of joint disease in horses. Vet Clin North Am Equine Pract 21: 713724.
  • 7
    Frisbie DD, Hague BA, Kisiday JD. 2007. Stem cells as a treatment for osteoarthritis. Presented at American College of Veterinary Surgeons Veterinary Symposium, Chicago, IL [available in digital format from the corresponding author].
  • 8
    Murphy JM, Fink DJ, Hunziker EB, et al. 2003. Stem cell therapy in a caprine model of osteoarthritis. Arthritis Rheum 48: 34643474.
  • 9
    Augello A, Tasso R, Negrini SM, et al. 2007. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum 56: 11751186.
  • 10
    Black LL, Gaynor J, Gahring D, et al. 2007. Effect of adipose-derived mesenchymal stem and regenerative cells on lameness in dogs with chronic osteoarthritis of the coxofemoral joints: a randomized, double-blinded, multicenter, controlled trial. Vet Ther 8: 272284.
  • 11
    Frisbie DD, Ghivizzani SC, Robbins PD, et al. 2002. Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther 9: 1220.
  • 12
    Kisiday JD, Kopesky PW, Evans CH, et al. 2008. Evaluation of adult equine bone marrow- and adipose-derived progenitor cell chondrogenesis in hydrogel cultures. J Orthop Res 26: 322331.
  • 13
    Anonymous. 1991. Definition and classification of lameness. In: Guide for veterinary service and judging of equestrian events. Lexington, KY: AAEP; p 19.
  • 14
    Farndale RW, Buttle DJ, Barrett AJ. 1986. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochem Biophys Acta 883: 173177.
  • 15
    Vick MM, Adams AA, Murphy BA, et al. 2007. Relationships among inflammatory cytokines, obesity, and insulin sensitivity in the horse J Anim Sci. 85: 11441155.
  • 16
    McFarlane D, Holbrook TC. 2008. Cytokine dysregulation in aged horses and horses with pituitary pars intermedia dysfunction. J Vet Intern Med 22: 436442.
  • 17
    Anonymous. 2006. The GLIMMIX Procedure. Cary, NC: SAS Institute Inc; 943 p.
  • 18
    May SA, Hooke RE. 1987. The identity of the E-series prostaglandins produced by chondrocytes and synovial cells in response to a variety of stimuli. Proc Br Equine Vet Assoc 26: 79.
  • 19
    May SA, Hooke RE, Lees P. 1989. Identity of the E-series prostaglandin produced by equine chondrocytes and synovial cells in response to a variety of stimuli. Res Vet Sci 46: 5457.
  • 20
    May SA, Hooke RE, Lees P. 1991. Adverse conditions in vitro stimulate chondrocytes to produce prostaglandin E2 and stomelysin. Equine Vet J 23: 380382.
  • 21
    May SA, Hooke RE, Lees P. 1992. Inhibition of interleukin-1 activity by equine synovial fluid. Equine Vet J 24: 99102.
  • 22
    Frisbie DD, Kawcak CE, Trotter GW, et al. 1998. The effects of 6-alpha methylprednisolone acetate on an in vivo equine osteochondral fragment exercise model. Am J Vet Res 12: 16191628.
  • 23
    Frisbie DD, Kawcak CE, Trotter GW, et al. 1997. The effects of triamcinolone acetate on an in vivo equine osteochondral fragment exercise model. Equine Vet J 29: 349359.
  • 24
    Frisbie DD, Kawcak CE, Werpy NM, et al. 2007. Clinical, biochemical and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis. Am J Vet Res 68: 290296.
  • 25
    Barry FP. 2003. Mesenchymal stem cell therapy in joint disease. Novartis Found Symp 249: 8696; discussion –102, 70–74, 239–241.
  • 26
    Im GI, Shin YW, Lee KB. 2005. Do adipose tissue-derived mesenchymal stem cells have the same osteogenic and chondrogenic potential as bone marrow-derived cells? Osteoarthritis Cartilage 13: 845853.
  • 27
    Hennig T, Lorenz H, Thiel A, et al. 2007. Reduced chondrogenic potential of adipose tissue derived stromal cells correlates with an altered TGFbeta receptor and BMP profile and is overcome by BMP-6. J Cell Physiol 211: 682691.
  • 28
    Liu TM, Martina M, Hutmacher DW, et al. 2007. Identification of common pathways mediating differentiation of bone marrow- and adipose tissue-derived human mesenchymal stem cells into three mesenchymal lineages. Stem Cells 25: 750760.
  • 29
    Noel D, Caton D, Roche S, et al. 2008. Cell specific differences between human adipose-derived and mesenchymal-stromal cells despite similar differentiation potentials. Exp Cell Res 314: 15751584.